<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/7FCAB171-FDF8-4A66-81C3-98B01B60B9AC" ns1:id="7FCAB171-FDF8-4A66-81C3-98B01B60B9AC"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/F9B7808A-D67C-4136-8433-A6C10CAD084B" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/76B86460-CE2B-42BF-A402-E3BB1712574D" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/76B86460-CE2B-42BF-A402-E3BB1712574D" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2017-12-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/7EE50E03-A205-4D89-B941-D041FDB6C159" ns1:rel="FUND" ns1:start="2017-01-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">132666</ns2:identifier></ns2:identifiers><ns2:title>A Carbohydrate Diagnostic for the Detection of Norovirus [CADDNOR]</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>ICENI Diagnostics provides point of care (POC) diagnostics and carbohydrate-based therapeutics, with a focus in infectious disease. A single device, dual assay human viruses, the subject of this proposal, has its basis in synthetic biology and is dependent on the assembly of recognition ligands using enzymatic production processes.. The developed assay uses glyconanoparticle technology with potential for replacing molecular technologies and immunodiagnostics – a major shift in analytical approach. It has potential applications in clinical and non-clinical settings. The company has research underpinning its developments and the technology has been demonstrated in lab and working environments. We now require investment to expedite the developmental process and introduce a paradigm shift in analysis by bridging the “valley of death” for SMEs, such as ours, as quickly as possible.</ns2:abstractText></ns2:project>